82 For patients with obesity and HFpEF, GLP-1 RAs, such as semaglutide, are safe, with fewer serious cardiovascular events reported
Data showed that despite severe nocturnal hypoxia over 10 nights not inducing substantial alterations in gut microbiota or inflammation, there were lower microbial diversity and enhanced insulin sensitivity
Across the study period, adverse events were generally consistent with trials of other incretin-based therapies and typically worsened with dose escalation (4 mg, 9 mg, 12 mg, vs
Centro de recursos Stephanie Al-Zubaidy aprendi de la peor manera sobre los efectos secundarios de los medicamentos GLP-1
As patients continue to undergo treatment, our team will adjust dosage to maintain top results